ivonescimab

Home
Ligands
ivonescimab

GtoPdb Ligand ID: 13396

Synonyms: AK-112 | AK112 | SMT-112 | SMT112

Comment: Ivonescimab (AK112/SMT112) is a first-in-class anti-programmed death-1 (PD-1)/VEGF-A bispecific monoclonal antibody. It is designed to simultaneously block both PD-1 and VEGF-mediated immunosuppression in the tumour microenvironment (TME) and inhibit the pro-angiogenic action of VEGF. Interaction of ivonescimab with VEGF-A increases the antibody's avidity for PD-1 and enhances the inhibitory effect on PD-1/PD-L1 signalling [4].

References
1. Frentzas S, Austria Mislang AR, Lemech C, Nagrial A, Underhill C, Wang W, Wang ZM, Li B, Xia Y, Coward JIG. (2024) Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors. J Immunother Cancer, 12 (4). [PMID:38642937]
2. HARMONi-A Study Investigators. (2024) Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant A Randomized Clinical Trial. JAMA, Online ahead of print. DOI: 10.1001/jama.2024.10613
3. Zhao Y, Chen G, Chen J, Zhuang L, Du Y, Yu Q, Zhuang W, Zhao Y, Zhou M, Zhang W et al.. (2023) AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClinicalMedicine, 62: 102106. [PMID:37593227]
4. Zhong T, Huang Z, Pang X, Jin C, He X, Xia Y, Li B, Min J. (2022) AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies. J Immunother Cancer, 10 (Suppl 2): A546–A547 Abstract. DOI: 10.1136/jitc-2022-SITC2022.0521

References

1. Frentzas S, Austria Mislang AR, Lemech C, Nagrial A, Underhill C, Wang W, Wang ZM, Li B, Xia Y, Coward JIG. (2024)
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
J Immunother Cancer, 12 (4). [PMID:38642937]

2. HARMONi-A Study Investigators. (2024)
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant A Randomized Clinical Trial.
JAMA, Online ahead of print. DOI: 10.1001/jama.2024.10613

3. Zhao Y, Chen G, Chen J, Zhuang L, Du Y, Yu Q, Zhuang W, Zhao Y, Zhou M, Zhang W et al.. (2023)
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.
EClinicalMedicine, 62: 102106. [PMID:37593227]

4. Zhong T, Huang Z, Pang X, Jin C, He X, Xia Y, Li B, Min J. (2022)
AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies.
J Immunother Cancer, 10 (Suppl 2): A546–A547 Abstract. DOI: 10.1136/jitc-2022-SITC2022.0521